Navigating the New Frontier in Cybersecurity: Technical and Regulatory Considerations for Managing Cybersecurity Risks for Combination Products
November 30 @ 11:40 am – 12:40 pm
This session will discuss FDA’s current thinking and expectations on addressing cybersecurity risks and also provide industry perspectives on the technical and regulatory cybersecurity considerations for combination products.
As combination products become increasingly integrated with device technologies that are connected to the internet, hospital networks, and mobile applications, they can become more vulnerable to cybersecurity threats. A 2022 report by the FBI indicated that 53% of connected medical devices had critical cybersecurity vulnerabilities. In addition, according to the FDA, cybersecurity threats to the healthcare sector have become more frequent and more severe, carrying increased potential for clinical impact. To address these emerging cybersecurity threats, the recently passed Consolidated Appropriations Act of 2023 includes several cybersecurity provisions, including new premarket requirements for manufacturers of cyber devices and related systems.
- Ryan Hoshi, Director, Regulatory Policy and Intelligence at AbbVie
- Edison Alvarez, Sr. Director, Regulatory Strategic Planning for Cybersecurity, BD
- Fubin Wu, Co-founder, GessNet Safety Engineering
- Aftin Ross, Acting Deputy Director – Division of All Hazards Response, Science & Strategic Partnerships, Center for Devices and Radiological Health (CDRH), FDA